Opinion|Videos|January 29, 2025

Patient Experiences, Key Clinical Trial Outcomes of the Port Delivery System

2

Panelists discuss how the Port Delivery System (PDS) presents important considerations around adverse effects, patient selection criteria, and adoption challenges including surgical requirements and cost-benefit analyses that must be carefully weighed when integrating this technology into retinal practice.

Video content above is prompted by the following:

  • Could you discuss the key outcomes from the ARCHWAY trial for PDS?
  • The PDS Q24W was noninferior to monthly ranibizumab in terms of BCVA change from baseline

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.


Latest CME